Literature DB >> 30594407

Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients.

Zhen-Li Li1, Jiong-Jie Yu1, Jun-Wu Guo1, Cheng-Jun Sui1, Bing-Hua Dai1, Wan-Guang Zhang2, Ting-Hao Chen3, Chao Li1, Wei-Min Gu4, Ya-Hao Zhou5, Hong Wang6, Yao-Ming Zhang7, Xian-Hai Mao8, Timothy M Pawlik9, Ming-Da Wang1, Lei Liang1, Han Wu1, Wan Yee Lau10, Meng-Chao Wu1, Feng Shen11, Tian Yang12.   

Abstract

BACKGROUND: The role of liver resection for multinodular (≥3 nodules) hepatocellular carcinoma (HCC) remains unclear, especially among patients with severe underlying liver disease. We sought to evaluate surgical outcomes among patients with cirrhosis and multinodular HCC undergoing liver resection.
METHODS: Using a multicenter database, outcomes among cirrhotic patients who underwent curative-intent resection of HCC were examined stratified according to the presence or absence of multinodular disease. Perioperative mortality and morbidity, as well as overall survival (OS) and recurrence-free survival (RFS) were compared between the two groups.
RESULTS: Among 1066 cirrhotic patients, 906 (85.0%) had single- or double-nodular HCC (the non-multinodular group), while 160 (15.0%) had multinodular HCC (the multinodular group). There were no differences in postoperative 30-day mortality and morbidity among non-multinodular versus multinodular patients (1.8% vs. 1.9%, P = 0.923, and 36.0% vs. 39.4%, P = 0.411, respectively). In contrast, 5-year OS and RFS of multinodular patients were worse compared with non-multinodular patients (34.6% vs. 58.2%, and 24.7% vs. 44.5%, both P < 0.001). On multivariable analyses, tumor numbers ≥5, total tumor diameter ≥8 cm and microvascular invasion were independent risk factors for decreased OS and RFS after resection of multinodular HCC in cirrhotic patients.
CONCLUSIONS: Liver resection can be safely performed for multinodular HCC in the setting of cirrhosis with an overall 5-year survival of 34.6%. Tumor number ≥5, total tumor diameter ≥8 cm and microvascular invasion were independently associated with decreased OS and RFS after resection in cirrhotic patients with multinodular HCC.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Hepatectomy; Hepatocellular carcinoma; Recurrence; Survival

Mesh:

Year:  2018        PMID: 30594407     DOI: 10.1016/j.ejso.2018.12.016

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

2.  Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases.

Authors:  Jian-Guo Chen; Jian Zhu; Yong-Hui Zhang; Yong-Sheng Chen; Lu-Lu Ding; Hai-Zhen Chen; Ai-Guo Shen; Gao-Ren Wang
Journal:  J Hepatocell Carcinoma       Date:  2021-08-31

3.  Is partial hepatectomy a curable treatment option for hepatocellular carcinoma accompanied by cirrhosis? A meta-analysis and cure model analysis.

Authors:  Byungje Bae; Keera Kang; Sung Kyu Song; Chul-Woon Chung; Yongkeun Park
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

4.  Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study.

Authors:  Jun-Yi Wu; Jia-Yi Wu; Yi-Nan Li; Fu-Nan Qiu; Song-Qiang Zhou; Zhen-Yu Yin; Yu-Feng Chen; Bin Li; Jian-Yin Zhou; Mao-Lin Yan
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

5.  Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Ismail Labgaa; Patrick Taffé; David Martin; Daniel Clerc; Myron Schwartz; Norihiro Kokudo; Alban Denys; Nermin Halkic; Nicolas Demartines; Emmanuel Melloul
Journal:  Liver Cancer       Date:  2020-01-28       Impact factor: 11.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.